{"altmetric_id":13504218,"counts":{"readers":{"mendeley":2,"citeulike":0,"connotea":0},"total":{"posts_count":1},"news":{"unique_users_count":1,"unique_users":["the_asco_post"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa4e83cf058f610002280","authors":["K. Harrington","R.L. Ferris","J. Shaw","F. Taylor","M. Derosa","D. Turner-Bowker","L. Morrissey","K. Cocks","N. Kiyota","M. Gillison","J. Guigay"],"doi":"10.1093\/annonc\/mdw435.30","first_seen_on":"2016-11-11T01:25:52+00:00","issns":["1569-8041"],"journal":"Annals of Oncology","last_mentioned_on":1478827518,"links":["http:\/\/annonc.oxfordjournals.org\/content\/27\/suppl_6\/LBA4_PR.full?sid=0dda1dbe-c153-4e0b-ad71-e34f9e35f049"],"pdf_url":"http:\/\/annonc.oxfordjournals.org\/content\/27\/suppl_6\/LBA4_PR.full.pdf","pubdate":"2016-10-01T00:00:00+00:00","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"title":"head and neck cancerPatient-reported outcomes (PROs) in recurrent or metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (nivo) or investigator\u2019s choice (IC): CheckMate 141","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/pr-patientreported-outcomes-pros-recurrent-metastatic-rm-squamous-cell-carcinoma-head-neck-scchn-tre"},"altmetric_score":{"score":7,"score_history":{"1y":7,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":7679268,"mean":6.5932591477757,"rank":1058009,"this_scored_higher_than_pct":85,"this_scored_higher_than":6552782,"rank_type":"exact","sample_size":7679268,"percentile":85},"similar_age_3m":{"total_number_of_other_articles":230575,"mean":12.948483454335,"rank":49391,"this_scored_higher_than_pct":77,"this_scored_higher_than":177865,"rank_type":"exact","sample_size":230575,"percentile":77},"this_journal":{"total_number_of_other_articles":3352,"mean":9.2058561623396,"rank":700,"this_scored_higher_than_pct":76,"this_scored_higher_than":2577,"rank_type":"exact","sample_size":3352,"percentile":76},"similar_age_this_journal_3m":{"total_number_of_other_articles":248,"mean":6.6824696356275,"rank":65,"this_scored_higher_than_pct":61,"this_scored_higher_than":153,"rank_type":"exact","sample_size":248,"percentile":61}}},"demographics":{"users":{"mendeley":{"by_status":{"Student  > Master":1,"Other":1},"by_discipline":{"Medicine and Dentistry":2}}}},"posts":{"news":[{"title":"Better Quality of Life Reported in Patients With Head and Neck Cancer Receiving Nivolumab vs Chemotherapy","url":"http:\/\/ct.moreover.com\/?a=28569170686&p=1pl&v=1&x=D5lW8ESJzfqPXHahFg3lVQ","license":"public","citation_ids":[13504218,12518175],"posted_on":"2016-11-11T01:25:18+00:00","summary":"Standard treatment for advanced head and neck cancer\u2014including chemotherapy and radiation\u2014causes painful side effects that impair quality of life, as well as the ability to socialize and engage in daily life activities.","author":{"name":"The ASCO Post","url":"http:\/\/www.ascopost.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/496\/normal\/Screen_Shot_2016-02-03_at_09.24.05.png?1454491455"}}]}}